This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-small cell lung cancer (NSCLC)	MicroRNA-205 (miRNA-205)	<p>Studies in human tissue samples suggest that miRNA-205 could be a biomarker of squamous NSCLC. In a set of 95 human NSCLC tissue samples, an miRNA-205-based assay was able to distinguish squamous NSCLC from nonsquamous NSCLC with 96% sensitivity and 90% specificity. Next steps include validating the miRview squamous test, which is based on the miRNA-205 assay, in a clinical setting. Rosetta Genomics Inc. markets miRview to differentiate between squamous and nonsquamous NSCLC.</p> <p>SciBX 2(12); doi:10.1038/scibx.2009.487 Published online March 26, 2009</p>	Multiple patents filed covering miRNA-205 composition, extraction, utilization and quantification; unavailable for licensing	<p>Lebanony, D. <i>et al.</i> <i>J. Clin. Oncol.</i>; published online March 9, 2009; doi:10.1200/JCO.2008.19.4134</p> <p>Contact: Ranit Aharonov, Rosetta Genomics Inc., Jersey City, N.J. e-mail: ranit_ah@rosettagenomics.com</p>